Editorial: the microbiome, aspirin and colorectal cancer
- PMID: 33205868
- DOI: 10.1111/apt.16071
Editorial: the microbiome, aspirin and colorectal cancer
Comment in
-
Editorial: the microbiome, aspirin and colorectal cancer-authors' reply.Aliment Pharmacol Ther. 2020 Dec;52(11-12):1742-1743. doi: 10.1111/apt.16115. Aliment Pharmacol Ther. 2020. PMID: 33205872 No abstract available.
Comment on
-
Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.Aliment Pharmacol Ther. 2020 Sep;52(6):976-987. doi: 10.1111/apt.16013. Epub 2020 Aug 8. Aliment Pharmacol Ther. 2020. PMID: 32770859 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762-769.
-
- Haykal T, Barbarawi M, Zayed Y, et al. Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2019;145:1795-1809.
-
- Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila). 2016;9:895-905.
-
- Murphy CL, OʼToole PW, Shanahan F. The gut microbiota in causation, detection, and treatment of cancer. Am J Gastroenterol. 2019;114:1036-1042.
-
- Prizment AE, Staley C, Onyeaghala GC, et al. Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. Aliment Pharmacol Ther. 2020;52:976-987.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical